On Wednesday 4th February, the Department of Health and Social Care and NHS England published it’s “National Cancer Plan for England: Delivering world class cancer
Jersey GP Surgery introduces Skin Analytics’ AI as a medical device DERM to offer patients earlier diagnosis and avoid unnecessary referrals to specialist services. First
Human Bytes has entered a strategic partnership with UK based Skin Analytics to bring the world’s only autonomous AI for assessment and triage of suspected
Following NICE’s conditional approval of DERM, our Class III CE-marked AI as a medical device for skin cancer detection, a new video feature in Nature
As seen at Affidea.com Affidea, a leading pan-European provider of community-based polyclinics, advanced diagnostics, and multi-specialist care, including oncology, has entered a strategic partnership with Skin
While the NHS 10-Year Health Plan highlights that by 2028 AI skin cancer pathways will be standard of care, this is not the timeline for adoption. Rather this timeline aligns with the expected timing to mandated adoption across the NHS.
Neil Daly, CEO & founder of Skin Analytics, appeared before the UK Parliament’s Science, Innovation and Technology Committee as part of the ongoing inquiry titled: “Innovation Showcase: Reviewing the UK Science and Tech Landscape.”
On May 1st 2025, the National Institute for Health and Care Excellence (NICE) published its Early Value Assessment (EVA) of ‘Artificial intelligence (AI) technologies for assessing and triaging skin lesions within the urgent suspected skin cancer pathway’.
Dr Alice Plant, Consultant Dermatologist at University Hospitals Dorset NHS Foundation Trust, and Dr Dilraj Kalsi, Clinical AI Lead at Skin Analytics joined Future Medicine AI Hub to discuss how AI is proving to transform NHS dermatology services.
In this week’s episode of The Scrubbed In Show podcast, our CEO Neil Daly shares his journey from consulting into building Skin Analytics.
We’re thrilled to share that Skin Analytics has been awarded a place on the G-Cloud 14 Framework, one of the UK government’s leading procurement frameworks for cloud software and services.
The BMA recently published their principles for Artificial Intelligence (AI) and its application in healthcare, so we thought this provides a great opportunity for us to share how we have implemented them at Skin Analytics over the last 5 years.
In a recent article from L’Atelier BNP Paribas, Alex Hadwick breaks down the quiet breakthrough of vision AI, and what the future looks like through its lenses.
Mentioning the work we’re doing here at Skin Analytics with the NHS, Streeting went on to say, ‘Reform is not just possible, it is happening. From AI detecting skin cancer and cutting waiting times to weight loss jabs slashing the risk of heart attacks for diabetes patients.’
Professor Lord Darzi’s latest report is confronting. But here is why our CEO, Neil Daly is optimistic about what it means for our NHS.
A new report commissioned by NHS England (NHSE): Evaluating Pathways for AI Dermatology in Skin Cancer Detection states Skin Analytics’ Artificial Intelligence as a Medical Device (AIaMD), DERM, can be used autonomously in the NHS.
Skin Analytics joins the Royal Society of Medicine, Digital Health Section podcast to discuss all things post-market surveillance.
It’s AI Appreciation Day so we’re celebrating the human behind our AI as a medical device – Dr Jack Greenhalgh, Skin Analytics’ AI Director.
Rishi Sunak and Skin Analytics were invited to a meet and greet at Woking Community Hospital to see the work being delivered at Woking Community Centre’s Diagnostic Hub.
Now a Class IIa medical device, DERM, uses machine learning algorithms to recognise the most common malignant, pre-malignant and benign skin lesions, including melanoma – the fifth most common cancer in the UK. Using a decade’s worth of research and development on skin lesions, it is designed to accelerate patient diagnosis and relieve pressure on the healthcare system.
We were delighted to see research into the publicly available skin cancer datasets many use to train AI systems to assess skin cancer published in The Lancet Digital Health last week.
Applying academic rigour to a long known issue around machine learning helps to educate the industry around one of the foundations on which AI systems are built; training data.
Created to accelerate the evaluation of Artificial Intelligence (AI) technologies within the NHS, the NHSX award is highly competitive and prestigious, with an extensive evaluation process. Being granted the award is a major validation of what we do at Skin Analytics and the effort we have put in to build strong foundations based on clinical evidence, regulatory rigor and proprietary AI.
Google’s announcement of the culmination of three years of work and a subsequent move into skin disease analysis at their developer conference earlier this week has led to a number of people approaching me to ask what does this mean for Skin Analytics?
We believe that all responsible AI companies providing services to the healthcare sector should comply with the code of conduct and we have written our response to the NHS AI Code of Conduct.
ISO 13485:2016 is an internationally recognised quality standard for medical devices and is a pre-requisite for registration as a class II medical device under the MDR. This accreditation represents another important milestone for the company and our mission to help more people survive skin cancer.
It is true, we are not a technology company… Perhaps I should explain? When we started our journey to bring better access to high quality
Having CNN come out and spend time with us was very exciting, if a little nerve racking. They asked us some very insightful questions and I believe that we responded with some well thought out answers.
Skin Analytics has been fortunate to work with Digital Catapult as it launched its Machine Intelligence Garage (MIG) programme.
The University of Heidelberg has published a paper in the Annals of Oncology that demonstrates the important role that artificial intelligence (AI) can play in melanoma detection.
The last thing we want to see is innovation being suppressed under volumes of red tape. At the same time, we’re trying to change healthcare, meaning that we’re dealing with people’s health and that’s not an area to “move fast and break things” for fairly obvious reasons.
